| 前收盘价格 | 1.40 |
| 收盘价格 | 1.40 |
| 成交量 | 1,488,667 |
| 平均成交量 (3个月) | 1,301,492 |
| 市值 | 574,822,912 |
| 价格/销量 (P/S) | 338.25 |
| 股市价格/股市净资产 (P/B) | 97.15 |
| 52周波幅 | |
| 利润日期 | 9 Nov 2026 |
| 营业利益率 (TTM) | -17,994.78% |
| 稀释每股收益 (EPS TTM) | -0.590 |
| 总债务/股东权益 (D/E MRQ) | 0.91% |
| 流动比率 (MRQ) | 10.96 |
| 营业现金流 (OCF TTM) | -121.30 M |
| 杠杆自由现金流 (LFCF TTM) | -114.20 M |
| 资产报酬率 (ROA TTM) | -28.29% |
| 股东权益报酬率 (ROE TTM) | -45.28% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | ProKidney Corp. | 混合的 | 看涨 |
AIStockmoo 评分
-1.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -1.50 |
|
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 30.05% |
| 机构持股比例 | 42.03% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Artia Global Partners Lp | 30 Jun 2026 | 1,806,939 |
| Brown University | 30 Jun 2026 | 1,000,000 |
该时间范围内无数据。
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合